Patents by Inventor Lawrence Klein

Lawrence Klein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Materials and methods for engineering cells and uses thereof in immuno-oncology
    Patent number: 11202802
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: December 21, 2021
    Assignee: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Materials and methods for engineering cells and uses thereof in immuno-oncology
    Patent number: 11191783
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: December 7, 2021
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
    Patent number: 11174469
    Abstract: The present disclosure provides materials and methods for treating a patient with one or more conditions associated with SOD1 whether ex vivo or in vivo. In addition, the present disclosure provides materials and methods for editing and/or modulating the expression of SOD1 gene in a cell by genome editing.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: November 16, 2021
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • Materials and methods for engineering cells and uses thereof in immuno-oncology
    Patent number: 11166985
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: November 9, 2021
    Assignee: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Materials and methods for engineering cells and uses thereof in immuno-oncology
    Patent number: 11135247
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: October 5, 2021
    Assignee: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY
    Publication number: 20210252060
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: April 12, 2021
    Publication date: August 19, 2021
    Applicant: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY
    Publication number: 20210236551
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: April 12, 2021
    Publication date: August 5, 2021
    Applicant: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Lawrence KLEIN
  • MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY
    Publication number: 20210236552
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: April 12, 2021
    Publication date: August 5, 2021
    Applicant: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Methods and systems to quantify and index correlation risk in financial markets and risk management contracts thereon
    Patent number: 11080789
    Abstract: Systems and methods for creating indicators to quantify and index correlation risk that is market-wide among a broad set of asset classes or portfolio specific relative to an investor's portfolio holdings. The present disclosure relates to risk management in financial markets, and in particular to systems and methods for quantifying and indexing correlation risk such that these indices can serve as underlying assets for futures and options or other financial instruments that investors would use to hedge against the risk.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: August 3, 2021
    Assignee: Economic Alchemy LLC
    Inventors: Giselle Claudette Guzman, Lawrence Klein
  • Materials and methods for engineering cells and uses thereof in immuno-oncology
    Patent number: 11071755
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: July 27, 2021
    Assignee: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Materials and methods for engineering cells and uses thereof in immuno-oncology
    Patent number: 11013767
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: May 25, 2021
    Assignee: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY
    Publication number: 20210108174
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: May 11, 2018
    Publication date: April 15, 2021
    Applicant: CRISPR THERAPEUTICS AG
    Inventors: Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Lawrence KLEIN
  • MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY
    Publication number: 20210085718
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: September 29, 2020
    Publication date: March 25, 2021
    Applicant: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Materials and methods for engineering cells and uses thereof in immuno-oncology
    Patent number: 10881689
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: January 5, 2021
    Assignee: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY
    Publication number: 20200405764
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: August 3, 2020
    Publication date: December 31, 2020
    Applicant: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY
    Publication number: 20200405761
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: July 29, 2020
    Publication date: December 31, 2020
    Applicant: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Materials and methods for engineering cells and uses thereof in immuno-oncology
    Patent number: 10857184
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: December 8, 2020
    Assignee: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY
    Publication number: 20200330518
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Application
    Filed: July 8, 2020
    Publication date: October 22, 2020
    Applicant: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • Materials and methods for engineering cells and uses thereof in immuno-oncology
    Patent number: 10736919
    Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: August 11, 2020
    Assignee: CRISPR Therapeutics AG
    Inventors: Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
  • COMPOSITIONS AND METHODS FOR TREATMENT OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)-RELATED DISORDERS
    Publication number: 20200248168
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with PCSK9 whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of PCSK9 gene in a cell by genome editing.
    Type: Application
    Filed: February 15, 2018
    Publication date: August 6, 2020
    Inventors: Ante Sven LUNDBERG, Samarth KULKARNI, Lawrence KLEIN, Yvonne Sarah ARATYN, Roman Lvovitch BOGORAD, Hari Kumar PADMANABHAN